Perspectives on communicating biomarker-based assessments of Alzheimer’s disease to cognitively healthy individuals

Manuscript Number: 

17-0813R1

Author(s): 
Shirlene Badger, Carol Brayne, Eline Bunnik, Ana Diaz, Karine Fauria, Jean Georges, Dianne Gove, Richard Milne, José-Luis Molinuevo, Edo Richard, Craig W. Ritchie, Katie Wells

Disclosures

Shirlene Badger

  • Nothing to Disclose

Carol Brayne

  • Nothing to Disclose

Eline Bunnik

  • Nothing to Disclose

Ana Diaz

  • Grants
    • Agency: 
      http://www.alzheimer-europe.org/Alzheimer-Europe/Statutes-and-Finances/Finances
      Dates: 
      2016-2017

Karine Fauria

  • Nothing to Disclose

Jean Georges

  • Grants
    • Agency: 
      http://www.alzheimer-europe.org/Alzheimer-Europe/Statutes-and-Finances/Finances
      Dates: 
      2016-2017

Dianne Gove

  • Grants
    • Agency: 
      http://www.alzheimer-europe.org/Alzheimer-Europe/Statutes-and-Finances/Finances
      Dates: 
      2016-2017

Richard Milne

  • Nothing to Disclose

José-Luis Molinuevo

  • Consulting Fees:
    Roche, MSD, Lilly, Axovant, Roche Diagnostics, IBL, Oryzon, Novartis, Eisai
    Lecture Fees:
    Biogen, Roche Diagnostics, Lilly, Lundbeck

Edo Richard

  • Nothing to Disclose

Craig W. Ritchie

  • Nothing to Disclose

Katie Wells

  • Nothing to Disclose